Found: 12
Select item for more details and to access through your institution.
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 2, p. 463, doi. 10.1007/s10637-015-0218-6
- By:
- Publication type:
- Article
Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2019, v. 68, n. 4, p. 609, doi. 10.1007/s00262-018-02295-4
- By:
- Publication type:
- Article
ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM).
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi17, doi. 10.1093/neuonc/noy148.063
- By:
- Publication type:
- Article
Regorafenib Prior to Selective Internal Radiation Therapy Using <sup>90</sup>Y-Resin Microspheres for Refractory Metastatic Colorectal Cancer Liver Metastases: Analysis of Safety, Dosimetry, and Molecular Markers.
- Published in:
- Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00624
- By:
- Publication type:
- Article
Phase II Study of Concurrent Radiation Therapy, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus as First-Line Treatment for Patients With Glioblastoma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2012, v. 10, n. 4, p. 240
- By:
- Publication type:
- Article
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
- Published in:
- Journal of Neuro-Oncology, 2019, v. 144, n. 2, p. 303, doi. 10.1007/s11060-019-03227-7
- By:
- Publication type:
- Article
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
- Published in:
- Journal of Neuro-Oncology, 2018, v. 140, n. 2, p. 317, doi. 10.1007/s11060-018-2955-9
- By:
- Publication type:
- Article
A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
- Published in:
- Journal of Neuro-Oncology, 2016, v. 129, n. 2, p. 281, doi. 10.1007/s11060-016-2172-3
- By:
- Publication type:
- Article
A Randomized, Double‐Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX‐427) in Patients with Previously Untreated Stage IV Non‐Squamous‐Non‐Small‐Cell Lung Cancer: The SPRUCE Trial.
- Published in:
- Oncologist, 2019, v. 24, n. 12, p. e1409, doi. 10.1634/theoncologist.2018-0518
- By:
- Publication type:
- Article